Biomarker Tied To Success Of GlobeImmune's Therapeutic Hep C Vaccine In Patients With Poor Prognosis
This article was originally published in The Pink Sheet Daily
Executive Summary
For GlobeImmune, the pharmacogenomic implications are important not only as a predictor of response to interferon, but also as a predictor of how the GI-5005 vaccine behaves. The company is tailoring its Phase III approach using that information.
You may also be interested in...
Hepatitis C Opportunities Light Up Infectious Disease Partnering Landscape
"Without question, hepatitis C is the number one exciting area in infectious diseases," insists Paul Zhang, a principal in the health care advisory group Easton Associates, LLC.
Hepatitis C Opportunities Light Up Infectious Disease Partnering Landscape
"Without question, hepatitis C is the number one exciting area in infectious diseases," insists Paul Zhang, a principal in the health care advisory group Easton Associates, LLC.
Prospect Of Predictive Gene Test Grips Developers Of Hepatitis C Drugs
The discovery of a gene marker that foretells the effectiveness of current standard-of-care therapy in hepatitis C offers a new tool for drug development and a potential guide for clinicians